Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

Avantor Inc.

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?

BLCO vs. AVTR: Which Stock Is the Better Value Option?

Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?

BLCO or AVTR: Which Is the Better Value Stock Right Now?

Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock

Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics

Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.

Bausch & Lomb's stock soars 11% after earnings beat

Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?

Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Should You Buy?

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Young Li - Jefferies Craig Bijou - Bank of America Joanne Wuensch - Citi Vijay Kumar - Evercore ISI Douglas Miehm - RBC Capital Markets Operator Good morning and welcome to the Bausch + Lomb Third Quarter 2023 Earnings Call. All participants will be in a listen-only mode.

Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript

The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to Say

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders is scheduled to participate at the 2023 Wells Fargo Healthcare Conference in Boston on Sept. 6, 2023, at 10:15 a.m. ET. A live webcast and audio archive of the conference will be available on the Investor Relations section of the Bausch + Lomb website. About Bausch + Lomb Bau.

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.29 per share a year ago.

Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates

Doximity

Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is more attractive to value investors?

BLCO or DOCS: Which Is the Better Value Stock Right Now?

Bausch Health Companies Inc

Novartis

LAVAL, QC / ACCESSWIRE / June 30, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (NYSE/TSX:BHC), announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.

Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA(R)

Cvent Holding Corp

Leonardo DRS Inc

Penske Automotive Group

Southern Copper

Vita Coco

Corsair Gaming

EverCommerce

Evolv Technologies Holdings

Fluence Energy

Flex Lng Ltd

Hercules Capital

Instructure Holdings

IonQ

LifeStance Health Group

Life Time Group Holdings

Nano-X Imaging

Symbotic Inc

Target Hospitality Corp

Tootsie Roll Industries

Stocks that are difficult to sell short are likely to be overvalued, a new study finds. These fit the bill.

20 Stocks That Look Like They're in Bubble Territory Right Now

Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Allison Ryan - ED, IR Brent Saunders - CEO and Chairman Sam Eldessouky - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Cecilia Furlong - Morgan Stanley Craig Bijou - Bank of America Merrill Lynch Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2023 Earnings Call. All participants will be listen-only mode.

Bausch + Lomb Corporation (BLCO) Q1 2023 Earnings Call Transcript

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.24 per share a year ago.

Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates

VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma™ Fully Digital Surgical Visualization Platform, which provides ophthalmic surgeons with a new level of visualization compared to optical, hybrid and retrofitted microscopes.

Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company.

Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

Intellia Therapeutics

SparingVision appoints Jo seph C. Papa as Chairman

SparingVision appoints Joseph C. Papa as Chairman

News for Bausch + Lomb Corp Stock (BLCO)